Table 4. ADCC-mediated target cell lysis by MT201 and trastuzumab.
| Cell line | No. of experiments | MT201a | Trastuzumaba | MT201 : trastuzumab |
|---|---|---|---|---|
| MT-3 | 4 | 47.7 (±28.1) | 20.5 (±7.2) | 2.3 : 1 |
| ZR-751 | 3 | 200.3 (±35.1) | 15.7 (±9.3) | 12.8 : 1 |
| MCF7 | 3 | 100.8 (±99.9) | 11.3 (±3.4) | 8.9 : 1 |
| MDA-MB-453 | 3 | 92.1 (±71.1) | 4.4 (±1.3) | 20.9 : 1 |
| BT20 | 3 | 311.5 (±47.7) | 138 (±106.7) | 2.3 : 1 |
| SKBR3 | 3 | 461.4 (±238.3) | 16.1 (±9.1) | 28.7 : 1 |
| MaTu | 3 | 262.3 (±249.0) | 112.7 (±86.6) | 2.3 : 1 |
| BT474 | 3 | 11.9 (±6.5) | 8.3 (±3.2) | 1.4 : 1 |
| MDA-MB-231 | 3 | N/A | 65.9 (±36.5) | N/A |
| KATO III | 13 | 84.6 (±57.7) | 117.3 (±71.1) | 1 : 1.4 |
Antibody concentrations that triggered half-maximal cell lysis by ADCC (see Figure 1) are shown. The assay used human PBMC effector cells at an E : T ratio of 20 : 1 in 4-h assay. Numbers give mean values from the indicated number of experiments and standard deviations. KATOIII cells served as reference cell line. N/A: not assessed.
a
EC50 values in ng ml−1.